BCLI — Brainstorm Cell Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $8.22m
- $8.03m
Annual cashflow statement for Brainstorm Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -31.8 | -24.5 | -24.3 | -17.2 | -11.6 |
| Depreciation | |||||
| Non-Cash Items | 2.72 | 1.37 | 1.68 | -3.04 | 0.657 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.32 | -3.43 | 2.99 | -0.496 | 1.63 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -35.2 | -26.3 | -19.3 | -20.5 | -9.09 |
| Capital Expenditures | -0.378 | -0.33 | -0.029 | -0.018 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -4.07 | 0.653 | 1.03 | 2.21 | 0.012 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | -4.45 | 0.323 | 0.998 | 2.19 | 0.012 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 76.9 | 6.97 | 0.238 | 19 | 7.97 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 37.3 | -19 | -18.1 | 0.713 | -1.11 |